Computational Life develops mathematical models for cardiogenic shock management, providing clinicians with precise decision-support tools that enhance treatment accuracy and patient outcomes. The company also offers regulatory support services and R&D advising, streamlining the approval process for medical devices and drugs through in-silico modeling.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinicians managing cardiogenic shock require precise decision-support tools to enhance treatment accuracy and improve patient outcomes. Navigating the regulatory approval process for new drugs and medical devices is complex and requires detailed evidence. Early-stage medical device and drug development lacks comprehensive simulation tools to drive innovation and experimentation.
Solution
Computational Life develops mathematical models for cardiogenic shock management, providing clinicians with patient-specific insights to improve treatment decisions. The company offers in-silico modeling to streamline the regulatory submission process for drugs and medical devices, creating detailed evidence and reports to meet regulatory requirements. Computational Life also provides R&D support by simulating a wide range of scenarios and outcomes, offering crucial insights to drive innovation and experimentation in early-stage development.
Target Audience
The primary customers are clinicians managing cardiogenic shock, stakeholders navigating regulatory approvals for drugs and medical devices, and researchers in early-stage medical device and drug development.
Features
- Mathematical models for cardiogenic shock management providing patient-specific insights.
- In-silico modeling for regulatory submissions, aligning with current guidelines.
- Simulation of various scenarios and outcomes for early-stage medical device and drug development.
- Generation of detailed evidence and reports for regulatory approval.